Valérie Calenda

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

keepMED Ltd. manufactures innovative devices for treating obstructive sleep apnea. It offers keePAP, a wearable device that comprises of a lightweight unobtrusive nasal interface and a miniature battery-operated control unit that is used for the treatment of obstructive sleep apnea. The company was founded by Rapoport Alex and is headquartered in Rishon Le Zion, Israel.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation.

Keranova SA designs and develops surgical equipment for various ophthalmologic indications that involve the anterior segment of the eye. The company was founded by Fabrizio Romano on September 4, 2015 and is headquartered in Saint-Etienne, France.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Physio-Assist SAS develops an expertise in bronchial mucus analysis and clearance. The company was founded by Adrien Mithalal on September 17, 2012 and is headquartered in Aix en Provence, France.

keepMED Ltd. manufactures innovative devices for treating obstructive sleep apnea. It offers keePAP, a wearable device that comprises of a lightweight unobtrusive nasal interface and a miniature battery-operated control unit that is used for the treatment of obstructive sleep apnea. The company was founded by Rapoport Alex and is headquartered in Rishon Le Zion, Israel.

Keranova SA designs and develops surgical equipment for various ophthalmologic indications that involve the anterior segment of the eye. The company was founded by Fabrizio Romano on September 4, 2015 and is headquartered in Saint-Etienne, France.

Keranova SA designs and develops surgical equipment for various ophthalmologic indications that involve the anterior segment of the eye. The company was founded by Fabrizio Romano on September 4, 2015 and is headquartered in Saint-Etienne, France.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

keepMED Ltd. manufactures innovative devices for treating obstructive sleep apnea. It offers keePAP, a wearable device that comprises of a lightweight unobtrusive nasal interface and a miniature battery-operated control unit that is used for the treatment of obstructive sleep apnea. The company was founded by Rapoport Alex and is headquartered in Rishon Le Zion, Israel.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

keepMED Ltd. manufactures innovative devices for treating obstructive sleep apnea. It offers keePAP, a wearable device that comprises of a lightweight unobtrusive nasal interface and a miniature battery-operated control unit that is used for the treatment of obstructive sleep apnea. The company was founded by Rapoport Alex and is headquartered in Rishon Le Zion, Israel.

Physio-Assist SAS develops an expertise in bronchial mucus analysis and clearance. The company was founded by Adrien Mithalal on September 17, 2012 and is headquartered in Aix en Provence, France.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

keepMED Ltd. manufactures innovative devices for treating obstructive sleep apnea. It offers keePAP, a wearable device that comprises of a lightweight unobtrusive nasal interface and a miniature battery-operated control unit that is used for the treatment of obstructive sleep apnea. The company was founded by Rapoport Alex and is headquartered in Rishon Le Zion, Israel.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

Keranova SA designs and develops surgical equipment for various ophthalmologic indications that involve the anterior segment of the eye. The company was founded by Fabrizio Romano on September 4, 2015 and is headquartered in Saint-Etienne, France.

Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation.

Keranova SA designs and develops surgical equipment for various ophthalmologic indications that involve the anterior segment of the eye. The company was founded by Fabrizio Romano on September 4, 2015 and is headquartered in Saint-Etienne, France.

keepMED Ltd. manufactures innovative devices for treating obstructive sleep apnea. It offers keePAP, a wearable device that comprises of a lightweight unobtrusive nasal interface and a miniature battery-operated control unit that is used for the treatment of obstructive sleep apnea. The company was founded by Rapoport Alex and is headquartered in Rishon Le Zion, Israel.

Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation.